07:00 , Apr 15, 2013 |  BC Week In Review  |  Company News

Quest Pharma, University of California deal

Quest PharmaTech received exclusive rights from the university to develop and market anti- prostate-specific antigen ( KLK3; PSA) IgE technology to treat cancer. The technology includes three pending patent applications that cover the use of...
07:00 , Oct 8, 2012 |  BC Week In Review  |  Company News

Advanced Immune Therapeutics, Quest Pharma deal

Quest acquired all of Advanced Immune's assets related to its AllergoOncology technology, including two pending U.S. patent applications and preclinical candidates for breast and prostate cancer. The technology, which was discovered in collaboration with the...
07:00 , Nov 4, 2010 |  BC Innovations  |  Targets & Mechanisms

Stemming ovarian cancer

A Boston team has identified ovarian cancer stem cells that may be responsible for the disease's high relapse rate.1 The group also discovered that a naturally occurring hormone called anti-Mullerian hormone can wipe out the...